We speculate that CRC tumors treated with Avelumab and ADC downregulate APOA1 and CCL16, among other genes, but preserve their viability despite increased oxidative stress, thanks to the activation of compensatory reductive pathways (such as pentose phosphate, malic enzyme or isocitrate dehydrogenases). This evidence concerns the gene CCL16 and colorectal carcinoma.